EP3417853A4 - Pharmazeutische zusammensetzung zur behandlung von krebs mit einer polyphenolverbindung als wirkstoff - Google Patents

Pharmazeutische zusammensetzung zur behandlung von krebs mit einer polyphenolverbindung als wirkstoff Download PDF

Info

Publication number
EP3417853A4
EP3417853A4 EP17753509.3A EP17753509A EP3417853A4 EP 3417853 A4 EP3417853 A4 EP 3417853A4 EP 17753509 A EP17753509 A EP 17753509A EP 3417853 A4 EP3417853 A4 EP 3417853A4
Authority
EP
European Patent Office
Prior art keywords
treatment
pharmaceutical composition
active ingredient
polyphenol compound
cancer containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17753509.3A
Other languages
English (en)
French (fr)
Other versions
EP3417853B1 (de
EP3417853A1 (de
Inventor
Jae Ho Cheong
Soo Youl Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
Industry Academic Cooperation Foundation of Yonsei University
National Cancer Center Korea
Original Assignee
National Cancer Center Japan
Industry Academic Cooperation Foundation of Yonsei University
National Cancer Center Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan, Industry Academic Cooperation Foundation of Yonsei University, National Cancer Center Korea filed Critical National Cancer Center Japan
Priority claimed from PCT/KR2017/001783 external-priority patent/WO2017142348A1/ko
Publication of EP3417853A1 publication Critical patent/EP3417853A1/de
Publication of EP3417853A4 publication Critical patent/EP3417853A4/de
Application granted granted Critical
Publication of EP3417853B1 publication Critical patent/EP3417853B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17753509.3A 2016-02-18 2017-02-17 Pharmazeutische zusammensetzung zur behandlung von magenkrebs mit gossypol, phenformin und irinotecan Active EP3417853B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160019255 2016-02-18
PCT/KR2017/001783 WO2017142348A1 (ko) 2016-02-18 2017-02-17 폴리페놀 화합물을 유효성분으로 포함하는 암 치료용 약학조성물

Publications (3)

Publication Number Publication Date
EP3417853A1 EP3417853A1 (de) 2018-12-26
EP3417853A4 true EP3417853A4 (de) 2019-10-30
EP3417853B1 EP3417853B1 (de) 2024-06-05

Family

ID=59759843

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17753509.3A Active EP3417853B1 (de) 2016-02-18 2017-02-17 Pharmazeutische zusammensetzung zur behandlung von magenkrebs mit gossypol, phenformin und irinotecan

Country Status (7)

Country Link
US (1) US10864178B2 (de)
EP (1) EP3417853B1 (de)
JP (1) JP6829723B2 (de)
KR (3) KR101904893B1 (de)
CN (1) CN108697667A (de)
HK (1) HK1257615A1 (de)
IL (1) IL261196B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101904893B1 (ko) * 2016-02-18 2018-10-10 연세대학교 산학협력단 폴리페놀 화합물을 유효성분으로 포함하는 암 치료용 약학조성물
KR102428313B1 (ko) 2018-07-09 2022-08-03 연세대학교 산학협력단 알데히드 억제제, 및 항암제를 포함하는 뇌암 치료용 약학조성물
KR102260846B1 (ko) * 2018-07-09 2021-06-07 국립암센터 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2020213939A1 (ko) * 2019-04-15 2020-10-22 주식회사 진센 항암제의 병용투여용 약학조성물
WO2020213938A1 (ko) * 2019-04-15 2020-10-22 주식회사 진센 사포닌을 유효성분으로 포함하는 암 치료용 약학조성물
KR102349477B1 (ko) * 2019-08-30 2022-01-10 (주)프론트바이오 바이구아나이드 계열 화합물 및 플라본, 하이드록시플라본, 플라바논, 플라본 유도체, 하이드록시플라본 유도체, 플라바논 유도체의 복합제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
KR102552913B1 (ko) * 2019-12-02 2023-07-07 주식회사 하임바이오 알데히드 억제제 및 비구아나이드 계열 화합물을 포함하는 속발성 암의 예방 및 치료용 약학조성물
KR20210084919A (ko) * 2019-12-30 2021-07-08 주식회사 하임바이오 Sglt-2 억제제 및 고시폴을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114805A1 (en) * 2009-03-31 2010-10-07 The Trustees Of The University Of Pennsylvania Methods of treating cancer with phenformin
WO2016126073A2 (ko) * 2015-02-02 2016-08-11 연세대학교 산학협력단 알데히드 억제제 및 비구아나이드 계열 화합물을 포함하는 암 줄기세포의 성장 억제용 약학적 조성물
EP3111931A1 (de) * 2014-02-27 2017-01-04 National Cancer Center Pharmazeutische zusammensetzung zur krebsbehandlung mit gossypol und phenformin als wirkstoffe
EP3254680A2 (de) * 2015-02-02 2017-12-13 Industry-Academic Cooperation Foundation, Yonsei University Pharmazeutische zusammensetzung zur hemmung des wachstums von krebsstammzellen mit aldehydinhibitor und verbindung auf der basis von biguanid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
WO2002097053A2 (en) 2001-05-30 2002-12-05 The Regents Of The University Of Michigan Small molecule antagonists of bcl2 family proteins
EP1732529A4 (de) 2004-03-25 2009-02-25 Univ Michigan Gossypol kokristalle und ihre verwendung
US20090175869A1 (en) 2007-05-31 2009-07-09 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
CA2689033A1 (en) 2007-05-31 2008-12-11 Ascenta Therapeutics, Inc. Pulsatile dosing of gossypol for treatment of disease
KR101289033B1 (ko) 2011-07-04 2013-07-23 한양대학교 산학협력단 암 줄기세포 성장 억제용 조성물
KR101904893B1 (ko) 2016-02-18 2018-10-10 연세대학교 산학협력단 폴리페놀 화합물을 유효성분으로 포함하는 암 치료용 약학조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114805A1 (en) * 2009-03-31 2010-10-07 The Trustees Of The University Of Pennsylvania Methods of treating cancer with phenformin
EP3111931A1 (de) * 2014-02-27 2017-01-04 National Cancer Center Pharmazeutische zusammensetzung zur krebsbehandlung mit gossypol und phenformin als wirkstoffe
WO2016126073A2 (ko) * 2015-02-02 2016-08-11 연세대학교 산학협력단 알데히드 억제제 및 비구아나이드 계열 화합물을 포함하는 암 줄기세포의 성장 억제용 약학적 조성물
EP3254680A2 (de) * 2015-02-02 2017-12-13 Industry-Academic Cooperation Foundation, Yonsei University Pharmazeutische zusammensetzung zur hemmung des wachstums von krebsstammzellen mit aldehydinhibitor und verbindung auf der basis von biguanid

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUNASSEKARAN G R ET AL: "In vitro and in vivo studies on antitumor effects of gossypol on human stomach adenocarcinoma (AGS) cell line and MNNG induced experimental gastric cancer", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 411, no. 4, 13 July 2011 (2011-07-13), pages 661 - 666, XP028382890, ISSN: 0006-291X, [retrieved on 20110713], DOI: 10.1016/J.BBRC.2011.06.167 *
JOON HEE KANG ET AL: "Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion", ONCOTARGET, vol. 7, no. 31, 2 August 2016 (2016-08-02), pages 49397 - 49410, XP055559244, DOI: 10.18632/oncotarget.10354 *
KATO KIYOHITO ET AL: "The Antidiabetic Drug Metformin Inhibits Gastric Cancer Cell Proliferation In Vitro and In Vivo", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 3, 1 March 2012 (2012-03-01), pages 549 - 560, XP002780384, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-11-0594 *
See also references of WO2017142348A1 *

Also Published As

Publication number Publication date
EP3417853B1 (de) 2024-06-05
IL261196A (en) 2018-10-31
KR20180045884A (ko) 2018-05-04
JP6829723B2 (ja) 2021-02-10
IL261196B (en) 2021-12-01
KR101904893B1 (ko) 2018-10-10
EP3417853A1 (de) 2018-12-26
HK1257615A1 (zh) 2019-10-25
KR20180045883A (ko) 2018-05-04
KR102192827B1 (ko) 2020-12-18
CN108697667A (zh) 2018-10-23
US10864178B2 (en) 2020-12-15
JP2019505522A (ja) 2019-02-28
KR20170097575A (ko) 2017-08-28
US20190388366A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
EP3417853A4 (de) Pharmazeutische zusammensetzung zur behandlung von krebs mit einer polyphenolverbindung als wirkstoff
FR25C1042I1 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
MX2019009187A (es) Compuesto de quinazolina.
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
BR112018010650A2 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
EP4663636A3 (de) Trifluoromethyl substituierte pyrazole als menschliche plasmakallikreinhemmer
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
SA521422152B1 (ar) Vanin مركبات عطرية غير متجانسة كمثبطات
EP3480186A4 (de) Neuartiges arylethanderivat und pharmazeutische zusammensetzung damit als wirkstoff
EP3539951A4 (de) Neuartige pyrimidinverbindung, verfahren zur herstellung davon und pharmazeutische zusammensetzung damit als wirkstoff zur prävention oder behandlung von krebs und entzündungserkrankungen
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EP2878305A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von stat3-vermittelten erkrankungen mit einem salvia plebeia-r. br.- extrakt oder einem teil davon als wirkstoff
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12017501130A1 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
EP3489252A4 (de) Peptid mit antikrebswirkung und pharmazeutische zusammensetzung zur prävention und behandlung von krebs, funktionelle lebensmittel zusammensetzung und funktionelle kosmetische zusammensetzung damit als wirkstoff
EP3372231A4 (de) Pharmazeutische zusammensetzung zum zwecke der krebsimmuntherapie und/oder immunstimulation mit heterozyklischer diamino-carboxamid-verbindung als wirkstoff
EP2910246A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von krebs mit enoblock als wirkstoff
EP3698801A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von diabetes, mit zinksalz, cyclo-hispro und antidiabetischem arzneimittel als wirkstoffe
EP3650029A4 (de) Pharmazeutische zusammensetzung zur vorbeugung und behandlung von diabetischer nephropathie mit adenosinderivat
EP3404020A4 (de) Pyridinolderivat oder pharmazeutisch unbedenkliches salz davon und pharmazeutische zusammensetzung damit als wirkstoff
EP4023234A4 (de) Pharmazeutische zusammensetzung mit vaccinia-virus und hydroxyharnstoff als wirkstoff zur behandlung von krebs
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
EP3327000A4 (de) Neuartige verbindung mit blt-hemmender wirkung und zusammensetzung damit als wirkstoff zur prävention oder behandlung von entzündlichen erkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191002

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/11 20060101ALI20190926BHEP

Ipc: A61P 35/00 20060101ALI20190926BHEP

Ipc: A61K 31/4745 20060101ALI20190926BHEP

Ipc: A61P 35/04 20060101ALI20190926BHEP

Ipc: A61K 45/06 20060101AFI20190926BHEP

Ipc: A61K 31/155 20060101ALI20190926BHEP

Ipc: A61K 31/36 20060101ALI20190926BHEP

Ipc: A61K 31/37 20060101ALI20190926BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201221

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/04 20060101ALI20240311BHEP

Ipc: A61P 35/00 20060101ALI20240311BHEP

Ipc: A61K 45/06 20060101ALI20240311BHEP

Ipc: A61K 31/4745 20060101ALI20240311BHEP

Ipc: A61K 31/155 20060101ALI20240311BHEP

Ipc: A61K 31/37 20060101ALI20240311BHEP

Ipc: A61K 31/36 20060101ALI20240311BHEP

Ipc: A61K 31/11 20060101AFI20240311BHEP

INTG Intention to grant announced

Effective date: 20240402

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240418

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017082411

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240905

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240906

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1691922

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241005

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017082411

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

26N No opposition filed

Effective date: 20250306

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602017082411

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250228

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20250217

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20250228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250217